aimovig drug insight and market forecast

“AIMOVIG Market Size, Forecast, and Drug Insight – 2032” report offers an in-depth analysis of both the market and emerging insights regarding  AIMOVIG for the treatment of Migraine and Chronic pain in the seven major markets. A detailed picture of the AIMOVIG in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the AIMOVIG The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments, including the AIMOVIG market forecast analysis in the 7MM, SWOT, analysts’ views, a comprehensive overview of market competitors, and a brief about other emerging therapies.

Drug Summary

AIMOVIG (erenumab), formerly AMG 334, is a human immunoglobulin G2 (IgG2) monoclonal antibody with high-affinity binding to the CGRP-R. AIMOVIG is an EMA and FDA-approved migraine prevention treatment designed specifically to block the CGRP-R, which plays a critical role in migraine.

Erenumab-aooe is produced using recombinant DNA technology in CHO cells. It comprises two heavy chains, each containing 456 amino acids, and two light chains of the lambda subclass containing 216 amino acids, with an approximate molecular weight of 150 kDa. AIMOVIG (erenumab-aooe) injection is supplied as a sterile, preservative-free, clear to opalescent, colorless to light yellow solution for SC administration. Enclosed within the autoinjector is a single-dose, prefilled glass syringe. The solution of AIMOVIG has a pH of 5.2.

Currently, AIMOVIG is being investigated for episodic migraine as well. Phase III trials were going in October 2020, and Amgen announced 5-year data that reinforced the safety and efficacy profile of AIMOVIG (erenumab-aooe) in adult patients with episodic migraine. Results of the Phase III EMPOwER study (NCT03333109) highlighted the efficacy and safety of AIMOVIG in adult patients with episodic migraine from Asia, the Middle East, and Latin America.

Mechanism of action

Erenumab-aooe is a human monoclonal antibody that binds to the CGRP receptor and antagonizes CGRP receptor function.

Dosage and administration

The recommended dosage of AIMOVIG is 70 mg injected subcutaneously once monthly. Some patients may benefit from a dosage of 140 mg injected subcutaneously once monthly. If a dose of AIMOVIG is missed, administer it as soon as possible. Thereafter, AIMOVIG can be scheduled monthly from the date of the last dose.

Dosage forms and strength

AIMOVIG is a sterile, clear to opalescent, colorless to light yellow solution available as follows:

• Injection: 70 mg/mL in a single-dose prefilled SureClick autoinjector
• Injection: 140 mg/mL in a single-dose prefilled SureClick autoinjector
• Injection: 70 mg/mL in a single-dose prefilled syringe
• Injection: 140 mg/mL in a single-dose prefilled syringe.

Scope of the Report

The report provides insights into:

• A comprehensive product overview includes the AIMOVIG description, mechanism of action, dosage and administration, and research and development activities in migraine and chronic pain.
• Elaborated details on AIMOVIG regulatory milestones and other development activities have been provided in this report.
• The report also highlights the AIMOVIG research and development activities in Migraine and Chronic pain across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around AIMOVIG.
• The report contains forecasted sales of for Migraine and Chronic pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Migraine and Chronic pain.
• The report also features the SWOT analysis with analyst views for AIMOVIG in Migraine and Chronic pain.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities' websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals, and access to available databases.

AIMOVIG Analytical Perspective by DelveInsight

In-depth AIMOVIG Market Assessment

This report provides a detailed market assessment of AIMOVIG for Migraine and Chronic pain in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

AIMOVIG Clinical Assessment

The report provides the clinical trials information of AIMOVIG for Migraine and Chronic pain, covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for Migraine and Chronic pain is set to change due to the extensive research and incremental healthcare spending across the world, which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• Companies are developing therapies that focus on novel approaches to treat/improve disease conditions, assess challenges, and seek opportunities that could influence AIMOVIG dominance.
• Other emerging products for Migraine and Chronic pain are expected to give tough market competition to AIMOVIG, and the launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones and developmental activities provides the current development scenario of AIMOVIG in Migraine and Chronic pain.
• Our in-depth analysis of the forecasted sales data of AIMOVIG from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of AIMOVIG in Migraine and Chronic pain.

Key Questions

• What is the product type, route of administration and mechanism of action of AIMOVIG?
• What is the clinical trial status of the study related to AIMOVIG in migraine and chronic pain, and what is the study completion date?
• What are the key collaborations, mergers and acquisitions, licensing, and other activities related to the AIMOVIG development?
• What are the key designations that have been granted to AIMOVIG for Migraine and Chronic pain?
• What is the forecasted market scenario of AIMOVIG for Migraine and Chronic pain?
• What are the forecasted sales of AIMOVIG in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available, and how are these competing with AIMOVIG for migraine and chronic pain?
• Which are the late-stage emerging therapies under development for the treatment of Migraine and Chronic pain?